The DANS services for sharing, cataloguing and archiving your health data

DANS (Data Archiving and Networked Services) is the Netherlands institute for permanent access to digital research resources. DANS encourages researchers to make their research data and related digital outputs Findable, Accessible, Interoperable and Reusable (FAIR). To realise our mission, DANS provides expert advice and certified services. DataverseNL is the DANS service for short‐term data management, EASY our long‐term data archive, and NARCIS the national catalogue service for scholarly information. Training and consultancy services are provided for generic Research Data Management and Data Management Planning. More specific training sessions focus on repository certification, metadata standards, software sustainability and knowledge organisation systems. The (coordinating) activities of DANS in (inter)national projects and networks, ensure constant innovation and a state‐of‐the‐art knowledge on infrastructural data developments. Although the roots of DANS are within the humanities and social sciences, most DANS services are generic services relevant for nearly all scientific disciplines, including the life and health sciences. As part of the Dutch national e‐infrastructure for research data, DANS is involved in several projects and initiatives around health data, often acting at the cross roads between the life and social sciences. Also, the DANS training activities touch upon the developments around health data. Cataloguing the Dutch “zorggegevens” in NARCIS, or the DANS training modules in the Helis Academy FAIR data stewardship course, are examples of specific DANS contributions to the life and health sciences. The DANS poster presentation provides an overview of the DANS services of interest to the owners and custodians of health data, including examples of relevant recent projects. DANS invites participants of the Health‐RI 2020 conference to probe how DANS could support the sharing, cataloguing and archiving of their health data

“Stap voor stap richting een nationale data-infrastructuur”: DANS lanceert domeingerichte Data Stations

Op verzoek van onderzoekers en dataprofessionals bewaart DANS bijna 200.000 datasets gegarandeerd duurzaam. Het KNAW/NWO-instituut is sinds 2006 een belangrijke speler binnen de Nederlandse en wereldwijde onderzoeksgemeenschap. De komende periode gaat DANS domeingerichte Data Stations aanbieden, diensten die zijn toegesneden op de behoeften binnen wetenschappelijke disciplines. Daarmee wordt DANS naast een archief voor datasets uit voltooide onderzoeksprojecten, ook een omgeving waarin onderzoekers datasets kunnen vormen, bewerken, analyseren en delen

DANS Data Game: Digital or Visual

DANS has developed a game especially for researchers: the DANS Data Game. The game gives an impression of the research data landscape and was specially produced for the 15th anniversary of DANS in 2020. The game is available in .pdf, DANS can send the game via postorder and the game can be played online. Visit dans.knaw.nl for more information

Eradication of carriage with methicillin-resistant Staphylococcus aureus: determinants of treatment failure

Background: Using data from an observational study in which the effectiveness of a guideline for eradication of methicillin-resistant Staphylococcus aureus (MRSA) carriage was evaluated, we identified variables that were associated with treatment failure. Methods: A multivariate logistic regression model was performed with subgroup analyses for uncomplicated and complicated MRSA carriage (the latter including MRSA infection, skin lesions, foreign-body material, mupirocin resistance and/or exclusive extranasal carriage) and for those treated according to the guideline (i.e. mupirocin nasal ointment and chlorhexidine soap solution for uncomplicated carriage, in combination with two oral antibiotics for complicated carriage). Results: Six hundred and thirteen MRSA carriers were included, of whom 333 (54%) had complicated carriage; 327 of 530 patients (62%) with known complexity of carriage were treated according to the guideline with an absolute increase in treatment success of 20% (95% confidence interval 12%-28%). Among those with uncomplicated carriage, guideline adherence [adjusted odds ratio (OR alpha) 7.4 (1.7-31.7)], chronic pulmonary disease [OR alpha 44 (2.9-668)], throat carriage [OR alpha 2.9 (1.4-6.1)], perineal carriage [OR alpha 2.2 (1.1-4.4)] and carriage among household contacts [OR alpha 5.6 (1.2-26)] were associated with treatment failure. Among those with complicated carriage, guideline adherence was associated with treatment success [OR alpha 0.2 (0.1-0.3)], whereas throat carriage [OR alpha 4.4 (2.3-8.3)] and dependence in activities of daily living [OR alpha 3.6 (1.4-8.9)] were associated with failure. Conclusions: Guideline adherence, especially among those with complicated MRSA carriage, was associated with treatment success. Adding patients with extranasal carriage or dependence in daily self-care activities to the definition of complicated carriage, and treating them likewise, may further increase treatment success.Antimicrobial treatment and prevention of infection

Eradication of carriage with methicillin-resistant Staphylococcus aureus: effectiveness of a national guideline

We evaluated the effectiveness of eradication of methicillin-resistant Staphylococcus aureus (MRSA) carriage in the Netherlands after the introduction of a guideline in 2006. The guideline distinguishes complicated (defined as the presence of MRSA infection, skin lesions, foreign-body material, mupirocin resistance and/or exclusive extranasal carriage) and uncomplicated carriage (not meeting criteria for complicated carriage). Mupirocin nasal ointment and chlorhexidine soap solution are recommended for uncomplicated carriers and the same treatment in combination with two oral antibiotics for complicated carriage. A prospective cohort study was performed in 18 Dutch centres from 1 October 2006 until 1 October 2008. Six hundred and thirteen MRSA carriers underwent one or more decolonization treatments during the study period, mostly after hospital discharge. Decolonization was achieved in 367 (60%) patients with one eradication attempt and ultimately 493 (80%) patients were decolonized, with a median time until decolonization of 10 days (interquartile range 7-43 days). Three hundred and twenty-seven (62%) carriers were treated according to the guideline, which was associated with an absolute increase in treatment success of 20% [from 45% (91/203) to 65% (214/327)]. Sixty percent of MRSA carriers were successfully decolonized after the first eradication attempt and 62% were treated according to the guideline, which was associated with an increased treatment succes

High treatment uptake in human immunodeficiency virus/ hepatitis C virus-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands

Background The Netherlands has provided unrestricted access to direct-acting antivirals (DAAs) since November 2015. We analyzed the nationwide hepatitis C virus (HCV) treatment uptake among patients coinfected with human immunodeficiency virus (HIV) and HCV. Methods Data were obtained from the ATHENA HIV observational cohort in which >98% of HIV-infected patients ever registered since 1998 are included. Patients were included if they ever had 1 positive HCV RNA result, did not have spontaneous clearance, and were known to still be in care. Treatment uptake and outcome were assessed. When patients were treated more than once, data were included from only the most recent treatment episode. Data were updated until February 2017. In addition, each treatment center was queried in April 2017 for a data update on DAA treatment and achieved sustained virological response. Results Of 23574 HIV-infected patients ever linked to care, 1471 HCV-coinfected patients (69% men who have sex with men, 15% persons who [formerly] injected drugs, and 15% with another HIV transmission route) fulfilled the inclusion criteria. Of these, 87% (1284 of 1471) had ever initiated HCV treatment between 2000 and 2017, 76% (1124 of 1471) had their HCV infection cured; DAA treatment results were pending in 6% (92 of 1471). Among men who have sex with men, 83% (844 of 1022) had their HCV infection cured, and DAA treatment results were pending in 6% (66 of 1022). Overall, 187 patients had never initiated treatment, DAAs had failed in 14, and a pegylated interferon-alfa–based regimen had failed in 54. Conclusions Fifteen months after unrestricted DAA availability the majority of HIV/HCV-coinfected patients in the Netherlands have their HCV infection cured (76%) or are awaiting DAA treatment results (6%). This rapid treatment scale-up may contribute to future HCV elimination among these patients

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

non present